Nucleix Ltd.

Nucleix Ltd. is a pioneering biotechnology research company dedicated to transforming cancer treatment through innovative liquid biopsy solutions. Specializing in early disease detection, Nucleix Ltd. is committed to providing accurate and sensitive testing options that enable timely intervention and improved patient outcomes.

Located at 3 Rehovot, Merkaz 76000, IL (Primary Address) and 10675 Sorrento Valley Rd, San Diego, California 92121, US, Nucleix Ltd. leverages advanced NGS-based and PCR-based technology to identify methylation changes, offering a groundbreaking approach to early-stage and recurring cancer detection. The company's flagship product, EpiCheck®, delivers highly accurate results while ensuring a seamless experience for physicians, patients, and the healthcare system. Nucleix Ltd. is focused on expanding its EpiCheck® franchise, with the Bladder EpiCheck® kit already CE-marked and available in Europe for bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. Furthermore, Nucleix Ltd. is actively advancing its Lung EpiCheck® test toward commercialization for high-risk individuals and evaluating additional tests for other high-risk diseases.

Nucleix Ltd. is at the forefront of cancer diagnostics, striving to make a significant impact on global healthcare. Nucleix Ltd. is dedicated to continuous innovation and the development of cutting-edge solutions that improve the lives of patients worldwide. We invite the manager of Nucleix Ltd. to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial development.